TCGA-A8-A09T-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 19
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.350
- PROTEIN_SECRETION+0.340
- MYC_TARGETS_V1+0.330
- E2F_TARGETS+0.280
- ESTROGEN_RESPONSE_EARLY+0.280
- DNA_REPAIR+0.260
- MTORC1_SIGNALING+0.250
- ESTROGEN_RESPONSE_LATE+0.240
- FATTY_ACID_METABOLISM+0.220
- ANDROGEN_RESPONSE+0.200
Top 10 suppressed
- NOTCH_SIGNALING-0.380
- ALLOGRAFT_REJECTION-0.350
- IL6_JAK_STAT3_SIGNALING-0.330
- IL2_STAT5_SIGNALING-0.320
- WNT_BETA_CATENIN_SIGNALING-0.310
- INTERFERON_GAMMA_RESPONSE-0.300
- HEDGEHOG_SIGNALING-0.270
- INTERFERON_ALPHA_RESPONSE-0.270
- KRAS_SIGNALING_DN-0.240
- TNFA_SIGNALING_VIA_NFKB-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12202419 | — | — | 0.808 |
| 2 | MBCProject_0946_T1_RNA | — | C | 0.777 |
| 3 | SRR8518238 | — | C | 0.775 |
| 4 | SRR33346944 | — | — | 0.764 |
| 5 | TCGA-CN-4730-01A-01R-1436-07 | — | — | 0.764 |
| 6 | MBCProject_6127_T2_RNA | — | B | 0.758 |
| 7 | TCGA-BH-A0H9-01A-11R-A056-07 | — | B | 0.747 |
| 8 | 20120126.LumB | — | B | 0.745 |
| 9 | TCGA-BH-A1FJ-01A-11R-A13Q-07 | — | B | 0.745 |
| 10 | SRR25617890 | — | B | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.190 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |